

---

# Hematologic Malignancies

**Series editor**

Martin Dreyling

München, Germany

This series of professional books provides in-depth information on all aspects of the diagnosis and treatment of different hematologic cancers, including clinical evaluation, imaging diagnosis, staging, current treatment strategies, novel targeted approaches, and evaluation of treatment response. Readers will also find coverage of methodological and research issues and factors that influence treatment outcome. Each volume is designed to serve both as a quick reference and as a comprehensive source of knowledge that will be invaluable in improving management of the malignancy under consideration. The volume editors and authors have been selected for their international reputations and acknowledged expertise. The series will appeal to hematologists and oncologists in hospitals or private practices, residents, and others with an interest in the field.

More information about this series at <http://www.springer.com/series/5416>

---

Georg Lenz • Gilles Salles  
Editors

# Aggressive Lymphomas

 Springer

*Editors*

Georg Lenz  
Department of Translational Oncology  
University-Hospital Münster  
Münster  
Germany

Gilles Salles  
Department of Hematology  
University Claude Bernard Lyon 1  
Pierre-Benite cedex  
France

ISSN 2197-9766

ISSN 2197-9774 (electronic)

Hematologic Malignancies

ISBN 978-3-030-00361-6

ISBN 978-3-030-00362-3 (eBook)

<https://doi.org/10.1007/978-3-030-00362-3>

Library of Congress Control Number: 2018964248

© Springer Nature Switzerland AG 2019, Corrected Publication 2019

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG  
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

---

# Contents

## Part I Epidemiology, Pathology and Molecular Pathogenesis

- 1 Epidemiology of Aggressive Lymphomas . . . . . 3**  
James R. Cerhan
- 2 Pathology and Molecular Pathogenesis of DLBCL  
and Related Entities . . . . . 41**  
Laura Pasqualucci and German Ott
- 3 Pathology and Molecular Pathogenesis of Burkitt  
Lymphoma and Lymphoblastic Lymphoma. . . . . 75**  
Hélène A. Poirel, Maria Raffaella Ambrosio, Pier Paolo  
Piccaluga, and Lorenzo Leoncini
- 4 Pathology and Molecular Pathogenesis  
of T-Cell Lymphoma . . . . . 95**  
Javeed Iqbal and Laurence de Leval

## Part II Standard of Care of Aggressive Lymphomas

- 5 Standard of Care in First-Line Therapy of DLBCL . . . . . 145**  
Greg Nowakowski, Fabian Frontzek, and Norbert Schmitz
- 6 Standard of Care Relapsed DLBCL . . . . . 157**  
Kayane Mheidly, Roch Houot, Michael Scordo,  
and Craig Moskowitz
- 7 Burkitt Lymphoma . . . . . 167**  
Kieron Dunleavy and Martine Chamuleau
- 8 Human Immunodeficiency Virus-Related Lymphomas . . . . . 177**  
Josep-Maria Ribera and Richard F. Little
- 9 Primary CNS Lymphoma. . . . . 189**  
Agnieszka Korfel
- 10 Extranodal Localization of Aggressive Lymphoma . . . . . 201**  
Jeremy S. Abramson and Armando López-Guillermo
- 11 CD20-Negative Aggressive Lymphomas . . . . . 213**  
Jorge J. Castillo

<b>12</b>	<b>Standard of Care in T-Cell Lymphoma</b> . . . . .	227
	Alessandro Broccoli, Dai Chihara, Michelle A. Fanale, and Pier Luigi Zinzani	
<b>13</b>	<b>Aggressive Lymphoma in Children and Adolescents</b> . . . . .	245
	Birte Wistinghausen and Birgit Burkhardt	
<b>Part III Future Directions in Aggressive Lymphomas</b>		
<b>14</b>	<b>Role of Modern Imaging with FDG-PET/CT in Aggressive Lymphoma</b> . . . . .	285
	Judith Trotman and Michel Meignan	
<b>15</b>	<b>Kinase Inhibitors in Large Cell Lymphoma</b> . . . . .	297
	Franck Morschhauser, Salomon Manier, and Nathan Fowler	
<b>16</b>	<b>Immunological Approaches</b> . . . . .	307
	Guillaume Cartron, F. Frontzek, and N. Schmitz	
<b>17</b>	<b>Therapeutic Modulators of Apoptosis and Epigenetics in Aggressive Lymphoma</b> . . . . .	325
	Michael J. Dickinson and John F. Seymour	
<b>18</b>	<b>Targeted Therapeutics for Lymphoma: Using Biology to Inform Treatment</b> . . . . .	343
	T. E. C. Cummin, M. S. Cragg, J. W. Friedberg, and P. W. M. Johnson	
	<b>Correction to: Aggressive Lymphomas</b> . . . . .	C1

---

# Introduction

In the last several years, the understanding of the biology and the molecular pathogenesis of aggressive lymphomas has substantially improved. This significantly changed diagnostic and therapeutic algorithms. As a result, a variety of novel molecular lymphoma subtypes and patient risk groups have recently been identified, and various novel and very specific compounds as well as new immunologic approaches have shown impressive efficacy in clinical trials. These therapeutic improvements will soon translate into standard of care and will further improve the prognosis of affected patients.

Our textbook summarizes the current knowledge on the epidemiology, pathology, and biology of the major aggressive lymphoma subtypes. In the main section, we provide an up-to-date overview of the standard of care therapeutic approaches of patients affected by these diseases. In the last part, we describe how we believe that the field will develop and how future diagnostic and therapeutic strategies will look like. Thus, our textbook provides an up-to-date compendium on the recent developments in the field of aggressive lymphomas.

At last, we would like to thank all of the authors whose expertise and tremendous efforts made the completion of this textbook possible. Finally, we are very grateful to the Springer publisher and especially to Ejaz Ahmad, who continuously supported the development of this textbook.

September 2018  
Münster, Germany  
Pierre-Benite cedex, France

Georg Lenz  
Gilles Salles

---

In the older version the spelling of book title was incorrect. Book title “Agressive Lymphomas” has been corrected to “Aggressive Lymphomas”. <https://doi.org/10.1007/978-3-030-00362-3>